To investigate the biological mechanism of the identified genetic interactions, we tested the associations of these interactions (PFDR < 0.1) with intermediate AD phenotypes including Aβ and tau protein levels, brain atrophy, and white matter injury. The gene discussed is MAPT; the disease is Alzheimer disease.